



MESCO

MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital- 263 001, Uttarakhand, India-19671261996
W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

Scrip ID: MESP HAR-B

Scrip Code: 500274

Sub: Audited Financial Results for the Quarter and Financial Year ended 31st March, 2019

This is reference to our letter dated 28.05.2019.

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Audited Financial Results for the Quarter and Year ended 31st March, 2019 duly considered and approved by the Board of Directors held at New Delhi on Tuesday, 28th May, 2019.

M/s. Sangram Paul & Co., Chartered Accountants, Statutory Auditors of the Company has issued Auditor's Report along with an unmodified opinion on the Audited Financial Results of the Company.

The Board meeting commenced at 3.30 P.M. and concluded at 4.55 P.M.

A Copy of the said results together with Auditors Report is enclosed herewith. These results are also being made available on the website of the Company at <http://www.mescopharma.com/>

This is for your information and records.

Thanking You,

Yours Faithfully,
For **Mesco Pharmaceuticals Limited**


N.S. Parameswaran
Company Secretary cum Compliance Officer

Encl: As above

MESCO PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019

		Part-I				(Figures in Rs.)
Particulars		Quarter ended			Year ended	
		31.03.2019 (Audited)	31.12.2018 (Un-Audited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
I	Revenue From Operations	-	-	-	-	-
II	Other Income	-	-	-	-	-
III	Total Income (I + II)	-	-	-	-	-
	EXPENSES					
	Cost of materials consumed	-	-	-	-	-
	Purchase of Stock-in Trade	-	-	-	-	-
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-	-	-	-	-
	Employee benefits expense	-	-	75,000	-	305,581
	Finance Cost	-	-	-	-	150
	Depreciation and amortisation expense	-	-	-	-	-
	Other Expenses	181,353	45,728	54,560	4,098,033	567,739
	Total Expenses (IV)	181,353	45,728	129,560	4,098,033	873,490
V	Profit/(loss) before exceptional items and tax (I-IV)	(181,353)	(45,728)	(129,560)	(4,098,033)	(873,490)
VI	Exceptional items	-	-	-	-	-
VII	Profit/(Loss) Before Tax (V-VI)	(181,353)	(45,728)	(129,560)	(4,098,033)	(873,490)
	Tax Expense:					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(181,353)	(45,728)	(129,560)	(4,098,033)	(873,490)
X	Profit/(Loss) from discontinued Operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X+XI)	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	(181,353)	(45,728)	(129,560)	(4,098,033)	(873,490)
XIV	Other Comprehensive Income	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Earnings/(Loss) Per Equity Share (for continuing operation):	(181,353)	(45,728)	(129,560)	(4,098,033)	(873,490)
XVI	Basic and Diluted (face value of Rs. 10 each)	197,381,000	197,381,000	197,381,000	197,381,000	197,381,000
XVII	Earnings/(Loss) Per Equity Share (for discontinued operation):	-	-	-	-	-
	Basic and Diluted (face value of Rs. 10 each)	-	-	-	-	-
XVIII	Earnings/(Loss) Per Equity Share (for discontinued and Continuing Basic and Diluted (face value of Rs. 10 each)	(0.01)	(0.00)	(0.01)	(0.20)	(0.04)

Notes

- The Company has adopted Indian Accounting Standards (IND AS) prescribed under the Companies Act, 2013 read with relevant rules thereunder, with effect from April 1, 2017 and accordingly these financial results have been prepared in accordance with the measurement and recognition principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with relevant rules made thereunder
- The results for Quarter and Financial Year ended on March 31, 2019 presented here are Ind-AS Compliant and Audited by the Statutory Auditors of the Company
- The above audited financial results for the quarter and year ended on March 31, 2019 have been reviewed by the Audit Committee and have been approved by the Board of Directors in its meeting held on 28th May, 2019
- The figures for the quarters ended March 31, 2019 are the balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended December 31, 2018 which were subject to limited review by the statutory Auditors of the Company.
- Previous year period figures have been rearranged and regrouped wherever necessary to make them comparable with current period figures.
- There were no manufacturing activities in the Company during the period under consideration

For and on Behalf of Board of Directors of
Mesco Pharmaceuticals Limited

Sameer Singh
Sameer Singh
Managing Director

Date: 5/28/2019

Place: New Delhi

Mesco Pharmaceuticals Limited

Statement of Assets & Liabilities			
(Figures in Rs.)			
S.No	Particulars	As at 31st March, 2019	As at 31st March, 2018
1	2	3	3
	ASSETS		
(1)	Non-Current Assets		
	(a) Property, Plant and Equipment	1,798,760	1,798,760
	(b) Capital work-in-progress	-	-
	(c) Investment Property	-	-
	(d) Goodwill	-	-
	(e) Other Intangible assets	-	-
	(f) Intangible assets under development	-	-
1	(g) Biological Assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	285,000	285,000
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified)	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	1,800
(2)	Current Assets		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Cash and cash equivalents	395,918	395,918
	(iv) Bank balances other than (iii) above	-	-
	(v) Loans	-	-
	(vi) Others (to be specified)	-	-
	(c) Current Tax Assets (Net)	-	-
	(d) Other current assets	-	-
	Total Assets	2,479,678	2,481,478
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	197,381,000	197,381,000
	(b) Other Equity	(306,530,026)	(302,431,994)
	LIABILITIES		
(1)	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	111,392,716	107,461,040
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (Net)	-	-
	(d) Other non-current liabilities	-	-
(2)	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	228,300	71,000
	(iii) Other financial liabilities (other than those specified in item (c))	-	-
	(b) other current liabilities	-	-
	(c) Provisions	7,688	432
	(d) Current Tax Liabilities (Net)	-	-
	Total Equity and Liabilities	2,479,678	2,481,478

For and on Behalf of Board of Directors of
Mesco Pharmaceuticals Limited

Sameer Singh
Managing Director
DIN: 06862254

Date : 5/28/2019
Place : New Delhi



MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital- 263 001, Uttarakhand. Tel: 9871862796

W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com

May 28, 2019

Bombay Stock Exchange
Department of Investor Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015 with respect to Audit Report for the quarter and year ended on March 31, 2019 with unmodified opinion.


Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we hereby confirm and declare that Statutory Auditors of the Company M/S Sangram Paul and Co., Chartered Accountants (M.No: 013015) have issued Auditors Report with unmodified opinion in respect of Audited Financial Results for the quarter and year ended on March 31, 2019 approved at Board Meeting held on May 28, 2019.

Kindly take the same on your record and acknowledge the receipt.

Thanking You!

For Mesco Pharmaceuticals Limited


Sameer Singh
Managing Director
DIN: 06862254

Sangram Paul & Co.

S.K.Paul. F.C.A
Chartered Accountant

Chartered Accountants

Plot No.-754/15, Jayadev Vihar, Bhubaneswar-751 013
Phone : 0674-2360863, Mob. : 9337116878

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Mesco Pharmaceuticals Ltd

1. We have audited the accompanying statement of quarterly standalone Ind AS financial results of Mesco Pharmaceuticals Limited ('the Company') for the quarter ended March 31, 2019 and for the year ended March 31, 2019 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation'), read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016 ('the Circular').

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors in their meeting held on 28th May, 2019 have been prepared on the basis of the related financial statements, which are in accordance with the Standalone Ind AS Financial Statements prescribed under Section 133 of the Companies Act, 2013 as applicable read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.

2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly standalone Ind AS financial results as well as the year to date results:
 - i. are presented in accordance with the requirements of the Regulation read with the Circular, in this regard; and
 - ii. give a true and fair view of the net profit including other comprehensive income and other financial information for the quarter ended March 31, 2019 and for the year ended March 31, 2019.



4. The figures for the quarter ended 31st March, 2019 are the balancing figures between audited figures in respect of the full financial year March 31, 2019 and published year to date figures upto December 31, 2018, being the date of the end of the 3rd Quarter of the current financial year, subjected to limited review by us.

**For Sangram Paul & Co.
Chartered Accountants
Firm Registration No. 308001E**

S.K.P.
**(S.K.Paul)
Proprietor
M.No. 013015**



**Date: 28.05.2019
Place: New Delhi**